Rheumatoid Arthritis Market and Epidemiology Forecast 2024-2034 Featuring Analysis of ATI-450 (Aclaris Therapeutics) and Olumiant/Baricitinib (Eli Lilly/Incyte)

Yahoo FinanceJun 26 00:36

Global LAG-3 Inhibitors Market, Drug Sales & Clinical Trials Market Report: Featuring Abeome, ABL Bio, Agenus, Akeso Biopharma, AnaptysBio, EpimAb Biotherapeutics, Immutep, Incyte and Y-Biologics

Yahoo FinanceJun 20 16:23

Analyst Expectations For Incyte's Future

6 analysts have shared their evaluations of Incyte (NASDAQ:INCY) during the recent three months, expressing a mix of bullish and bearish perspectives.The table below provides a snapshot of their recen

BenzingaJun 18 22:01

Cantor Fitzgerald Reiterates Neutral on Incyte

Cantor Fitzgerald analyst Eric Schmidt reiterates Incyte (NASDAQ:INCY) with a Neutral.

BenzingaJun 18 21:46

Incyte Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/18/2024 — Cantor Fitzgerald Reiterates → Neutral 05/23/2024 -12.27% Deutsche Bank → $55 Initiates Cove

BenzingaJun 18 21:45

Research Alert: CFRA Keeps Buy View On Shares Of Incyte Corporation

CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: Following the solid rally seen Incyte Co

MT NewswiresJun 18 01:40